Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren's syndrome

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 9, 2007, Pages 1145-1146

  Makino, Shintaro ^a   Yonemoto, Hisashi ^a   Itoh, Shigeru ^a   Takeda, Satoru ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL HEART BLOCK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTIBODIES, ANTINUCLEAR; FEMALE; GLUCOCORTICOIDS; HEART BLOCK; HUMANS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS; PREDNISOLONE; PREGNANCY; PREGNANCY COMPLICATIONS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 34548321503     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701343024     Document Type: Article

References (2)

1. Dörner T, Feist E, Pruss A, Chaoui R, Göldner B, Hiepe F. Significance of antibodies in neonatal lupus erythematosus. Int Arch Allergy Immunol. 2000;123:58-66.
2. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with flurionated glucocorticoids to the natural histry of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. 1999;42:2335-45.